The former x-cardiac GmbH has broadened its business focus and is now operating as Ascléa GmbH. At the same time, the Berlin-based start-up has successfully completed a Series A funding round to drive the further development of its AI solutions for everyday clinical practice.

Ascenion’s portfolio company sThesis GmbH is selected as one of eight international teams to receive up to EUR 1.5 million in the first phase of a SPRIND Challenge to develop novel sensor technologies for continuous hormone monitoring.

PROVIREX is expanding and has consolidated its research, quality control and production operations at tecHHub Hamburg. The start-up is driving forward its clinical development of curative HIV therapies whilst also offering contract manufacturing of CAR-T cells at its new premises.

Following a successful End-of-Phase II meeting, the US Food and Drug Administration (FDA) has given the green light for OMEICOS’ drug candidate OMT-28 to proceed directly into a pivotal Phase III clinical trial. This could significantly shorten the path to regulatory approval.

The Helmholtz Centre for Infection Research (HZI) in Brunswick has been nominated for the Falling Walls Foundation’s ‘Science Breakthrough of the Year 2026’ with two projects. The nominations recognize work on antibiotics and vaccines.

The investigational candidate ITM-31 demonstrated a manageable safety profile across all cohorts, as well as early signs of efficacy in patients with glioblastoma that had undergone standard therapy. All enrolled patients remain alive during ongoing follow-up.

Dr Mario González García has been supporting our team in Munich and Berlin as a Technology Scout since June. He is a biochemist by training and brings valuable experience in the field of life-science venture capital.

Leading research institutions, technology transfer offices and venture capital investors in Germany have announced the launch of a jointly developed framework designed to enhance research-based spin-offs.

The Portuguese Champalimaud Foundation has acquired a portfolio of assets from Medigene Immunotherapies GmbH, together with the execution of an exclusive licence agreement with Helmholtz Munich for key chimeric co-stimulatory receptor technologies.

In spring 2026, projects from the Helmholtz Centre for Infection Research (HZI) in Brunswick received funding awards at both the German Biotech Days in Leipzig and Transfer X MACHEN – IBT Life Science Edition in Hanover.

Dr Sunčana Kern has just joined our Munich team as Technology Scout. With 15 years’ experience in biotechnology, she brings extensive expertise in the pharmaceutical development and GMP manufacturing of innovative cell and gene therapies.

Thanks to funding from the German Federal Ministry of Research, Technology and Space (BMFTR), 30 project leaders from GO-Bio initial projects were able to attend BioVaria, one of the most important annual events for the European life-science community.

SynuCa Therapeutics and Panosome win Startup Pitch & Partner Awards

Ascenion is looking forward to its annual reunion with industry decision makers, venture capitalists, academic inventors and entrepreneurs. Ten of around 60 projects to be featured originate from Ascenion’s academic partners. 

This first clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function in X-CGD patients. SB100X, a transposase licensed to Ensoma by Ascenion’s partner institute Max Delbrück Center, plays a key role in this context. 

Prague, Czech Republic

Ankara, Turkey

Cologne, Germany